SpaceX Just Delivered a Monster Quarter, but the Stock Is Still Down 38% From Its High. The Reasons Are Obvious.

SpaceX reported Q3 revenue growth of 161% and $2.8B in consolidated operating income, versus a $273M operating loss a year earlier; Starlink revenue rose 69% to $5.2B, while Super Intelligence revenue surged 830% to $7.6B. The stock was roughly $140 on Nov. 2, down 38% from its June peak, amid IPO lockup-related potential share supply, a still-high $1.9T valuation (39x expected 2026 sales), and $19.6B of Q3 capex. The article sees potential for gradual accumulation but flags financing needs, uncertain returns on AI infrastructure spending, and likely volatility.

Analysis

The key issue is conversion, not growth: operating profitability does not establish that the expansion is self-funding when reported capex is so large. If investment is financed with debt, returns depend on sustained utilization and pricing for AI capacity; weaker demand could leave assets underused while financing costs remain. That makes the reported operating profit a poor standalone proxy for the equity’s cash-generation capacity.

Near term (days to 1–3 months), newly eligible shares can create a technical supply overhang independent of fundamentals. Watch actual insider/early-holder sales and trading liquidity rather than treating eligibility as proof of selling. Over 6–18 months, the test is whether capacity agreements with Anthropic (ANT) and Alphabet (GOOG), plus other customer demand, translate into durable utilization and cash flow—not merely booked revenue. Customer bargaining power is a second-order risk: added industry compute supply could constrain pricing even if demand keeps growing.

Contrarian read: the sell-off may be partly flow-driven, but that does not make the valuation inexpensive. A high growth rate can coexist with weak equity returns if capex, funding needs, or dilution absorb the incremental economics. The thesis improves if capex intensity eases while operating cash flow catches up; it weakens if debt issuance expands without evidence of utilization. Verify cash-flow statements, financing terms, customer concentration, and actual lockup sales before sizing.

Key Decisions for Investors

• Avoid chasing SPCX during the near-term share-release window. Treat it as a watchlist/underweight until actual selling pressure is absorbed; eligibility alone is not a sell signal.
• For investors seeking exposure, consider a small staged long only after lockup-related supply is visible and the next results show improving operating cash flow relative to capex. Add only if utilization and customer commitments support the capacity build.
• Do not use ANT or GOOG as automatic hedges: the article does not quantify their purchase commitments or the effect on their costs. Reassess any relative-value trade after disclosures clarify contract size, duration, and pricing.
• Falsify the cautious view if SPCX demonstrates sustained cash-flow conversion as capex moderates and new share supply is absorbed. Tighten risk or step aside if debt needs rise while utilization, pricing, or guidance deteriorates.